Atezolizumab plus Bevacizumab after first-line multikinase inhibitors for advanced hepatocellular carcinoma: The concept of "drug class change"
- PMID: 37137807
- DOI: 10.1016/j.dld.2023.04.006
Atezolizumab plus Bevacizumab after first-line multikinase inhibitors for advanced hepatocellular carcinoma: The concept of "drug class change"
Conflict of interest statement
Declaration of Competing Interest Carlo Saitta has served as a consultant or on advisory boards for Eisai, Ipsen and Intercept/Advanz Pharma. Giuseppe Cabibbo has served as a consultant or on advisory boards for Bayer, Eisai, Ipsen, MSD, AstraZeneca, Roche.
Comment on
-
Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors.Dig Liver Dis. 2023 Jul;55(7):938-944. doi: 10.1016/j.dld.2023.03.005. Epub 2023 Apr 3. Dig Liver Dis. 2023. PMID: 37019737
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources